Sec Form 3 Filing - CSL LTD @ Cara Therapeutics, Inc. - 2022-08-09

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person CSL LTD 2. Issuer Name and Ticker or Trading Symbol Cara Therapeutics, Inc. [ CARA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 655 ELIZABETH STREET 3. Date of Earliest Transaction (MM/DD/YY) 08/09/2022 (Street) MELBOURNE VIC, C33000 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock, par value $0.001 per share 7,396,770 I See Notes ( 1 ) ( 2 ) ( 3 ) ( 4 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other CSL LTD 655 ELIZABETH STREET MELBOURNE VIC, C33000 X Signatures CSL LIMITED, By: /s/ Fiona Mead, Name: Fiona Mead, Title: Company Secretary 07/25/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )CSL Limited, an Australian public limited company ("CSL"), may be deemed to have a pecuniary interest in securities reported by it on this Form 3 (the "Subject Securities"). ( 2 )CSL's beneficial ownership of the Subject Securities is being reported solely because CSL may be deemed to beneficially own the Subject Securities as a result of its acquisition, indirectly, of 100% of the equity interests in Vifor Pharma Ltd. ("Vifor Pharma"), and, in turn, 100% of the equity interests in the entity that holds the Subject Securities, Vifor (International) Ltd. ("Vifor (International)"), and 55% of the equity interests in Vifor Fresenius Medical Care Renal Pharma Ltd. ("VFMCRP"), which were indirectly owned by Vifor Pharma, on August 9, 2022. VFMCRP may be deemed to beneficially own 6,221,943 of the Subject Securities as a result of its right to acquire such Subject Securities upon exercise of an option granted to it by Vifor (International). ( 3 )(Continued from Footnote 2) As a result of the merger of Vifor Pharma into Vifor Pharma Participations Ltd. ("Vifor Participations") pursuant to a merger agreement, dated May 11, 2023, CSL indirectly owns 100% of the equity interests in Vifor (International) and 55% of the equity interests in VFMCRP through its indirect ownership of 100% of the equity interests in Vifor Participations. ( 4 )CSL disclaims any beneficial ownership of any of the Subject Securities, except to the extent of any pecuniary interest therein.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.